Vascular levels and cGMP-increasing effects of nicorandil administered orally to rats

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 4, 1998, Pages 595-600

  Sakai, Kazushige ^a   Moriyasu, Matsuko ^a,b   Kitajima, Shunichi ^a,b   Akima, Michitaka ^a   Kamachi, Shinichi ^a   Tanikawa, Masahiko ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Panapharm Laboratories Co Ltd   (Japan)

Author keywords

Oral nicorandil and rats; Plasma and vascular concentrations of nicorandil; Vascular cGMP

Indexed keywords

ACETYLCHOLINE; ANTIANGINA PECTORIS AGENT; CARBON 14; CROMAKALIM; CYCLIC GMP; GLIBENCLAMIDE; METHYLENE BLUE; NICORANDIL; NORADRENALIN BITARTRATE; PAPAVERINE; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; ISOTOPE LABELING; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; THORACIC AORTA; VASODILATATION;

ADMINISTRATION, ORAL; ANIMALS; AORTA, THORACIC; CYCLIC GMP; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NIACINAMIDE; NICORANDIL; POTASSIUM CHANNELS; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS;

EID: 0031955067     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199804000-00019     Document Type: Article

References (22)

1. Sakai K, Nakano H, Nagano H, Uchida Y. Nicorandil. In: Scriabine A, ed. New drug annual: cardiovascular drugs. New York: Raven Press, 1983:227-39.
2. Sakai K. Nicorandil: animal pharmacology. Am J Cardiol 1989; 63: J2-10.
3. Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther 1990;4:1075-88.
4. Wagner G. Selected issues from an overview on nicorandil: tolerance, duration of action, and long-term efficacy. J Cardiovasc Pharmacol 1992;20:S86-92.
5. Suryapranata H. The cardiovascular profile of nicorandil. Rev Contemp Pharmacother 1993;4:204-14.
6. Krumenacker M, Roland E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol 1992;20:S93-102.
7. Sakai K, Ohba Y, Akima M, Kamiyama H, Hinohara H, Nakano H. Pharmacodynamic and metabolism studies on a new coronary vasodilator, N-(2-hydroxyethyl)nicotinamide nitrate (SG-75). Jpn J Pharmacol 1980;30:881-90.
8. Sakai K, Akima M, Hinohara Y, Obatake N. Hypotensive effects and biotransformation of nicorandil, a new antianginal agent, administered to rats by different routes: comparison with nitroglycerin and isosorbide dinitrate. J Pharm Pharmacol 1984;36: 175-81.
9. Frydman AM. Pharmacokinetic profile of nicorandil in humans: an overview. J Cardiovasc Pharmacol 1992;20:S34-44.
10. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
11. Ignarro LJ, Kadowitz PJ. The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol 1985;25:171-91.
12. Ahlner J, Andersson RGG, Torfgard K, Axelsson KL. Organic nitrate esters: clinical use and mechanisms of actions. Pharmacol Rev 1991;43:351-423.
13. 2+ by cAMP in vascular smooth muscle. Am J Physiol 1990;258:C399-407.
14. Karaki H, Sato K, Ozaki H, Murakami K. Effects of sodium nitro-prusside on cytosolic calcium level in vascular smooth muscle. Eur J Pharmacol 1988;156:259-66.
15. 2+ desensitization of skinned rat artery. Eur J Pharmacol 1997;323:75-82.
16. Kukovetz WR, Holzmann S, Poch G. Molecular mechanism action of nicorandil. J Cardiovasc Pharmacol 1992;20:S1-7.
17. + channel opening and guanylate cyclase stimulation to its vasorelaxant effects on various endothelin-1-contracted arterial preparations: comparison to aprikalim (RP 52891) and nitroglycerin. J Pharmacol Exp Ther 1991;259:526-33.
18. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989;63:18J-24.
19. Greenberg SS, Cantor E, Ho E, Walega M. Comparison of nicorandil-induced relaxation, elevations of cyclic guanosine monophosphate and stimulation of guanylate cyclase with organic nitrate esters. J Pharmacol Exp Ther 1991;258:1061-71.
20. Trongvanichnam K, Mitsui-Saito M, Ozaki H, Karaki H. Effects of chronic oral administration of a high dose of nicorandil on in vitro contractility of rat arterial smooth muscle. Eur J Pharmacol 1996; 314:83-90.
21. Lefer DJ, Lefer AM. Studies on the mechanism of the vasodilator action of nicorandil. Life Sci 1988;42:1907-14.
22. Morrison KJ, Flavahan NA, Vanhoutte PM. Differential effects of the antianginal drug nicorandil on canine arteries and veins. J Cardiovasc Pharmacol 1990;15:791-8.